Nano X Imaging Ltd (NNOX)

Triple Top Breakout on 4 June 2026. GLTA
At Close $2.07 change +$0.20 (+10.70%). Good.

Bought 5k more at $1.73

Grabbed another 10k @ 2.36

X

In Double Top Breakout pattern/mode since 14 Apr 2026. GLTA

I just bought 5,000 more at $2.47. Honestly this is the worst performing stock in my portfolio but it will no doubt come back so I averaged down a bit.

I like the technology and it will catch on, I can see one of these in every instant care joint in the country. 110 volts, very low radiation, instant AI results. Tis only a matter of time.

X. This will be another 10 bagger.

Nanox Teams Up with Meir Medical Center on Orthopedic Imaging StudyApril 14, 2026 8:51 AM
IH Market News
Nanox Imaging Ltd. (NASDAQ:NNOX) has entered into a clinical collaboration with Meir Medical Center to assess the diagnostic effectiveness of its Nanox.ARC system for orthopedic injuries in emergency care settings.The study will compare imaging results from the Nanox.ARC with the hospital’s current diagnostic approach, which typically involves standard X-rays or X-rays followed by CT scans. The objective is to determine whether Nanox’s system can deliver more detailed anatomical insights and enable faster clinical decisions in cases involving trauma and high-impact injuries.The Nanox.ARC is a multisource digital tomosynthesis platform designed to generate 3D images at a lower cost and with reduced radiation exposure compared to conventional CT scans. It is intended for tomographic imaging across areas such as the musculoskeletal system, lungs, abdomen, and sinuses in adult patients.“This collaboration with Meir Medical Center advances the ongoing real-world clinical validation of the Nanox.ARC,” said Erez Meltzer, CEO and Acting Chairman of Nanox. “Partnerships with leading institutions like Meir, one of Israel’s largest hospital networks, are essential to building the clinical evidence base that will support broader adoption of our technology.”Professor Nissim Ohana, Head of the Orthopedic Division at Meir Medical Center, said the study will test the system in live emergency scenarios, with the potential to enhance fracture detection.The research will also examine whether introducing Nanox.ARC at early triage stages can improve efficiency and reduce radiation exposure within the diagnostic pathway. The study will be conducted under a formal protocol approved by Meir’s Helsinki Committee.Meir Medical Center, part of Clalit Health Services, serves around one million residents in Israel’s Sharon region. The 801-bed hospital handles more than 60,000 admissions and approximately 190,000 emergency visits each year.Nanox Imaging stock price

Original: Nanox Teams Up with Meir Medical Center on Orthopedic Imaging Study

Bearish Signal Reversed on 1 Apr 2026. GLTA

Whats up here

They just signed an agreement for distribution across the South East U.S.

I have a small boat load of this that has been underwater since I bought it. Finally it is getting past all of the hurdles of a new device and with walk in clinics popping up on every corner it will soon find a home in them. Small light and operates on 120 volts, and checks from multiple angles with less radiation than an X-ray. And arc that moves in an arc to look behind in real timexwith an AI reader, not someone halfway across the world.

To the clinics it will be another revenue generating tool in the tool box and save patients from having to go to another imaging lab.

X

AI Medical Imaging Revolution: Software-Native Tech Disrupts $45B MarketJanuary 27, 2026 3:14 PM
PR Newswire (Canada)

ISSUED ON BEHALF OF VENTRIPOINT DIAGNOSTICS LTD.VANCOUVER, BC, Jan. 27, 2026 /CNW/ -- USANewsGroup.com News Commentary – The global medical imaging market hit a massive $45.5 billion in 2026[1], marking a total structural shift toward AI-native precision as advanced cancer therapies demand more intense heart monitoring than ever before[2]. Hospitals are ditching expensive, bulky hardware for agile, cloud-based platforms that deliver MRI-quality results without the MRI-sized price tag. This pivot has catapulted the cardiac AI diagnostic sector to $2.22 billion this year[3], driven by a desperate need for continuous imaging to catch heart dysfunction caused by cancer treatments[4]. This high-stakes convergence positions VentriPoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF), Butterfly Network (NYSE: BFLY), RadNet (NASDAQ: RDNT), Nanox Imaging (NASDAQ: NNOX), and OneMedNet (NASDAQ: ONMD) as the essential engineering nodes where software-defined 3D modeling finally solves radiologist shortages.







Leading programs at institutions like the Mayo Clinic are proving that subscription-based imaging is the ultimate "cheat code" for patient care, turning diagnostic accuracy into measurable ROI through Device-as-a-Service frameworks[5]. By using cloud-enabled solutions to manage complex heart risks, these companies are building high-margin, recurring revenue streams that align perfectly with the new world of value-based care. This isn't just a tech upgrade; it's a total reimagining of how the world tracks heart health for life.Ventripoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF) is building a subscription business around technology that converts standard 2D ultrasound images into detailed 3D heart models with MRI-level accuracy. The system delivers precise cardiac assessments at a fraction of the cost and complexity of traditional MRI imaging.Strong investor demand recently doubled the company's private placement from $500,000 to $1 million. The capital will fund commercialization activities, manufacturing scale-up, regulatory submissions across additional markets, and operational requirements as the company transitions from development to revenue generation.The latest strategic move focuses on proving economic value rather than just clinical capability. Ventripoint engaged Summit Sciences, a specialized healthcare consulting firm, to develop ROI models that show hospitals exactly what they will save. These models integrate real-world data to demonstrate measurable returns through process improvements, enhanced diagnostic accuracy, and optimized resource allocation."We are excited to partner with Dana and Summit Sciences to elevate our financial modeling capabilities," said Hugh MacNaught, President and CEO of Ventripoint Diagnostics. "Dana's extensive expertise in healthcare transformation, combined with Summit Sciences' proven track record in data-driven consulting, will enable us to deliver even more compelling value propositions to our customers. This initiative underscores our commitment to not only advancing cardiac care through technology but also ensuring that our solutions make strong economic sense for healthcare providers worldwide."Dana Friesen leads Summit Sciences as CEO, bringing more than 15 years of experience in financial analysis and ROI optimization within the medical device sector. The firm has delivered billions in cumulative savings for clinical partners. Friesen's work with indigenous health networks aligns with Ventripoint's expansion into underserved markets.The company announced a partnership with Nisga'a Valley Health Authority establishing a model for delivering advanced cardiac imaging to remote and Indigenous communities. The collaboration uses a hub-and-spoke design where local providers acquire ultrasound scans and transmit them digitally to specialists at a central hub for rapid interpretation.Ventripoint appointed David Swetlow as Chief Financial Officer. Swetlow brings more than 15 years of senior management experience from high-growth medical technology companies including Sernova, Ondine, Protox, HealthPricer, and QLT. Management views the appointment as a key step in executing a commercial strategy designed to accelerate market adoption and drive revenue growth.The company also issued a corporate update detailing its Device-as-a-Service subscription model. Management believes this approach shortens sales cycles and builds recurring revenue streams while making the technology accessible to more healthcare facilities without requiring large upfront capital investments.CONTINUED… Read this and more news for VentriPoint Diagnostics at:  https://usanewsgroup.com/2025/11/21/the-mri-grade-disruption-hiding-in-plain-sight-why-the-smart-money-is-watching-ventripointIn other industry developments and happenings in the market include:Butterfly Network (NYSE: BFLY) announced plans to release its Beam Steering API in first half 2026, marking the first time third-party developers will access digital 3D beam steering capabilities for AI-enabled ultrasound applications. The API leverages the company's proprietary semiconductor chip technology featuring approximately 9,000 elements that enable software-defined beam steering with off-axis tilt up to 20 degrees without mechanical motion."As the first to offer digital beam steering access to developers, Butterfly Network is changing the game for imaging AI, empowering more advanced tools that simplify image acquisition," said Steve Cashman, Chief Business Officer of Butterfly Network. "As our platform evolves, Butterfly partners gain access to more of our core imaging capabilities, allowing them to build richer, more sophisticated applications."The planned SDK access will support advanced imaging workflows across multiple presets including abdominal, cardiac, obstetric, musculoskeletal, vascular, and lung imaging. Butterfly Network continues expanding its Butterfly Garden and Ultrasound-on-Chip co-development programs, with availability and technical details dependent on ongoing development, regulatory considerations, and partner agreements to democratize ultrasound technology across clinical settings.RadNet (NASDAQ: RDNT) has acquired Radiology Regional, a division of LucidHealth serving Southwest Florida, expanding RadNet's footprint to 13 locations across Naples, Cape Coral, Fort Myers, Port Charlotte and Sarasota. The acquisition adds approximately 400 employees and 44 contracted radiologists to RadNet's operations, with the transaction projected to contribute approximately $100 million in revenue during 2026."RadNet is proud to enter a dynamic region of Florida and build on Radiology Regional's well-trusted history," said Steve Forthuber, President and CEO of Eastern Operations for RadNet. "Through our clinical excellence, operations expertise and AI-powered digital health solutions, RadNet intends to bring accessible and affordable leading-edge patient care, population health screening programs and a focus on early detection of disease to the communities of Southwest Florida."The 13 acquired centers provide comprehensive multi-modality imaging including MRI, CT, PET/CT, mammography, ultrasound and X-ray services built over Radiology Regional's half-century history. RadNet plans to deploy its DeepHealth AI-powered innovations across the acquired facilities to increase clinical accuracy, streamline imaging processes and improve patient experience in the rapidly growing Southwest Florida market.Nanox Imaging (NASDAQ: NNOX) has expanded operations across Serbia, Montenegro, and Bosnia and Herzegovina through a strategic collaboration with Adriamed d.o.o. Beograd, a Belgrade-based medical device distributor. The engagement brings the Nanox.ARC multi-source digital tomosynthesis system to healthcare providers throughout the Western Balkans region."We are building momentum in Europe through this strategic collaboration with Adriamed, whose expertise and regional reach will support our commercial expansion in the Western Balkans," said Erez Meltzer, CEO and Acting Chairman of Nanox Imaging. "Our strategy centers on expanding access to cost-effective imaging solutions through established regional partners."Under the agreement, Adriamed becomes Nanox Imaging's exclusive partner for the Nanox.ARC system and related services across the three-country region. The collaboration follows recent distribution agreements in Greece, Romania, Czech Republic and France as Nanox Imaging continues building its European commercial footprint.OneMedNet (NASDAQ: ONMD) has supported FDA 510(k) clearance of mlHealth 360's Scaida BrainCT-ICH, an AI-powered software solution for rapid detection of intracranial hemorrhage from head CT scans. OneMedNet's regulatory-grade Real-World Data spanning longitudinal electronic medical records, diagnostic imaging, and clinical reports played a critical role in supporting model development, validation, and regulatory submission for the software that analyzes head CT images in approximately 5.97 seconds."We are proud to collaborate with our premier partner mlHealth 360 and to support their efforts in advancing patient care through clinically impactful AI," said Aaron Green, CEO and President of OneMedNet. "Seeing OneMedNet's regulatory-grade Real-World Data—enriched with medical imaging and EMR context—contribute directly to an FDA-cleared solution reinforces the value of high-quality data in accelerating meaningful innovation."This milestone validates OneMedNet's position as a leading Real-World Data provider as life science and AI companies increasingly rely on OneMedNet to support FDA submissions. The depth, diversity, and quality of OneMedNet's curated imaging and clinical datasets enabled mlHealth 360 to access fit-for-purpose data while maintaining data integrity and regulatory compliance.Article Source: https://usanewsgroup.com/2025/11/21/the-mri-grade-disruption-hiding-in-plain-sight-why-the-smart-money-is-watching-ventripointCONTACT:USA NEWS GROUP
info @acblanke1DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). This article is being distributed for Baystreet.ca media Corp, who has been paid a fee for an advertising campaign. MIQ has not been paid a fee for Ventripoint Diagnostics Ltd. advertising or digital media, but the owner/operators of MIQ also co-owns Baystreet.ca Media Corp. ("BAY") There may also be 3rd parties who may have shares of Ventripoint Diagnostics Ltd. and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ/BAY own shares of Ventripoint Diagnostics Ltd and reserve the right to buy and sell, and will buy and sell shares of Ventripoint Diagnostics Ltd. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ on behalf of BAY has been approved by Ventripoint Diagnostics Ltd.; this is a paid advertisement, we currently own shares of Ventripoint Diagnostics Ltd. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.SOURCES:1.   https://www.grandviewresearch.com/industry-analysis/medical-imaging-systems-market
2.   https://www.bloomberg.com/news/articles/2026-01-23/new-potent-cancer-treatments-are-raising-heart-risks-for-survivors
3.   https://www.grandviewresearch.com/industry-analysis/artificial-intelligence-in-cardiology-market-report
4.   https://www.jacc.org/doi/10.1016/j.jaccao.2025.08.001
5.   https://link.springer.com/article/10.1186/s40959-016-0014-2 Logo - https://mma.prnewswire.com/media/2838876/5737507/USA_News_Group_Logo.jpg 



View original content to download multimedia:https://www.prnewswire.com/news-releases/ai-medical-imaging-revolution-software-native-tech-disrupts-45b-market-302671377.html

Original: AI Medical Imaging Revolution: Software-Native Tech Disrupts $45B Market

Double Top Breakout on 25-Nov-2025. GLTA

NNOX 10c of 🧲 hold into tomorrow

NNOX 4.90 magnetic 🧲 field coming

NNOX 4.90 magnetic field 🧲

NNOX the AI nano bio beast ready for beastville

NNOX here we go

Good news on the sales and distribution front.
X Tis going to happen.

NNOX continues its push north

NNOX.................................https://stockcharts.com/sc3/ui/?s=NNOX&p=W&b=5&g=0&id=p86431144783

Symbol NNOX
Last $4.40
Change +$0.95 (+27.39%) wowi wowu!
Bid $4.39
Ask $4.40
High $4.48
Low $3.53
Volume 11,250,829
Time (ET) 01:50:45 PM

Cheers & GLTA

NNOX the monster of monster AI nano imaging

NNOX.................................https://stockcharts.com/sc3/ui/?s=NNOX&p=W&b=5&g=0&id=p86431144783

NNOX happy with that exit

NNOX monster

NNOX explosion

NNOX big gapper

NNOX........https://stockcharts.com/sc3/ui/?s=NNOX&p=W&b=5&g=0&id=p86431144783

Eats alright 3.24 +15% image partnership nothing crazy 

NNOX mini bio beast

NNOX reporting 3rd Q financials on November 20th.

Double Top Breakout on 15-Oct-2025. GLTA

Share price in Bearish Signal Reverse mode since 3-Oct-2025. GLTA

So foot in the door in the U.S. in Sarasota Florida to demonstrate and train folks in the healthcare industry about its benefits.

X. Sounds like a tax deductible trip to Florida may be in order for the Healthcare cats.

Share price in Ascending Triple Top Breakout pattern since 6-Jun-2025. GLTA

Nanox Receives MDR CE Mark in Europe for HealthOST, an Advanced AI-Powered Software for Spine Assessment after it identified over 3,450 new patients with vertebral compression fractures from 37,220 CT scans.

Sounds pretty impressive.

X

Where you think we heading? Earnings Thursday thanks

I kind of think that an X-ray company with an established sales force will take this over and grab this technology.  120 volts easy set up, AI reads the results and highlights the anamolies, a couple hundred buck change.  80% of the time there is no need for a referral, yes you have a tiny fracture, this is not totally a U.S. thing but a Zimbabwe add to to a remote health care facility for a couple thousand bucks, plug it in.
X

Can you imagine every urgent care facility buying one of these for $10k.   The market is off the charts.   120 volts.  Easy install and AI software that reads and highlights the questionable area. No need to wait. Times they are a changing.

There are 10 of those urgent care facilities within 1 mile of my home. Kaching$!

X  I get it.

FDA 501 (k) clearance approved for "general use". They still need to approve the labeling, but they are free to market and produce it.

This is a 120 volt imaging machine that is cheap and easy to install, watch the video on the nano-X imaging.

The images are produced from multiple angles as the head is shaped like an arc and moves in an arc so that if something blocks the typical slice this can see beneath it.  Pretty cool.

Good luck.

Grabbed another 10k at 6 bucks ish.

X

Just Today NANO-X IMAGING LTD an innovative medical imaging technology company, today announced that it has received CE (Conformité Européenne) mark certification to market the multi-source Nanox.ARC system, including the Nanox.CLOUD, its accompanying cloud-based infrastructure. Nanox.ARC is a stationary X-ray system, intended to generate tomographic images of human anatomy from a single tomographic sweep performed in recumbent positions of adult patients.

And check it out it plugs into a 110 Volt Outlet. Not like an Expensive MRI machine.

X

This is 14 Month old info. I wanted to put it here tp compare to the ext 20-F (like a 10K)
Outside the U.S. market, we have entered into 13 MSaaS agreements to deploy a total of 7,125 Nanox Systems in 19 regions, including in Europe, South and Central America, Asia, Australia, New Zealand, Russia and Africa. Under the current terms of each agreement, we grant the other party a limited, non-transferable, sub-licensable right to access and operate the Nanox System in the region applicable for such party. We undertake to provide a specified number of Nanox Systems to each entity based on agreed shipment schedules, subject to local regulatory approval and material compliance with acceptance test protocol (the “Conditions Precedent”). The other party undertakes to deploy the Nanox Systems to provide a minimum number of scans per year (generally based on 7 scans per day and 23 days per month) on a pay-per-scan basis, and to pay a minimum annual fee (including payments to our partners) ranging from approximately $2 million to $58 million, or approximately $155 million in total, excluding the payments to our partners. The MSaaS agreements, subject to certain conditions, require each of our counterparties to deliver to us a standby letter of credit or financial guarantee in the amount equal to the minimum annual fee in favor of us after receipt of the Conditions Precedent. However, there can be no guaranty that our counterparties will be able to obtain such letters of credit or financial guarantees. In addition, a majority of our MSaaS agreements are exclusive; however, under several agreements, we may seek alternative partners in the applicable region while maintaining the possibility to eventually resume the agreement, if the requisite regulatory authorizations are received.
x

I'm in 10k shares @ $7.13 this technology is quite impressive.

It takes an X-ray from multiple angles (kind of like a few cameras on your cell phone) and if an organ, a cast, fluid from an adema, a rod, a screw or object is above or below in today's technology you get "noise" this enables the technical to focus above or below the "noise" for a clearer image. Place your finger in the air and focus on your finger, open and close your eyes, notice how you can see what is behind that finger.

Look at the 18:00 minute mark (watch it for a few minutes) in this video for a reason that every facility is going to have one of these.
While CT scans do today use multiple angles resolution is .6 to .4 at best for CT scans, Tomosynthis (Tomo) is .1 to .2 .




Looks like it does not replace todays CT's, MRI's there are advantages and disadvantages for all three but the physician will need to order DTS in addition to properly diagnose problems.

It can also diagnose pneumonia days earlier, even characterize some abnormalities quickly, so they can either be addressed or ignored. We all know how that goes, "we think we see something?" and they order test after test.

X Thoughts?

Interesting, might start a position. 

NNOX MONSTER COMPANY

NNOX JAN PLAY HITTING HARD

Nnox share price Long Tail Up since 05 Dec 2024.

NNOX BREAKING 9 BUCKS

NNOX EXPLOSION COMING

NNOX SMALL CAP PLAY READY TO GO HARD OFF MASSIVE VOL